HTR1D
ENSG00000179546
Target class
GPCR
Chromosome
1
Approved drugs
14
Clinical candidates (approved and in development)
17
- Approved drugs
- 14
- Clinical candidates (approved and in development)
- 17
- Chemical probe available
- Yes
- Target name
- HTR1D
- Gene name
- 5-hydroxytryptamine receptor 1D
- Gene symbol
- HTR1D
- Previous gene symbols
- HTRL
- Protein name
- 5-hydroxytryptamine receptor 1D (5-HT-1D) (5-HT1D) (Serotonin 1D alpha receptor) (5-HT-1D-alpha) (Serotonin receptor 1D)
- RDC4
- HT1DA
- 5-HT1D
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 8.89
- Tissue specificity (Gini)
- 0.851
- Tissue specificity (tau)
- 0.961
- KEGG gene identifiers
- hsa:3352
- Protein interaction confidence
- 0.794619
- Protein interaction partners
- 21
- R-HSA-390666
- R-HSA-418594
- End position
- 23217547
- Start position
- 23190178
- Chromosome
- 1
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- PubMed 10452531
- PubMed 1565658
- PubMed 1652050
- Tissue specificity (tau)
- 0.960736
- Expression inequality (Gini)
- 0.85098
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 8.89
- Brain - Caudate (basal ganglia)
- 4.93
- Brain - Putamen (basal ganglia)
- 3.65
- Small Intestine - Terminal Ileum
- 3.4
- Brain - Cortex
- 0.8
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)8.89
- Brain - Caudate (basal ganglia)4.93
- Brain - Putamen (basal ganglia)3.65
- Small Intestine - Terminal Ileum3.4
- Brain - Cortex0.8
- Testis0.65
- Brain - Frontal Cortex (BA9)0.65
- Brain - Hypothalamus0.6
- Brain - Amygdala0.57
- Nerve - Tibial0.43
- Brain - Anterior cingulate cortex (BA24)0.33
- Pituitary0.28
- Lung0.27
- Brain - Spinal cord (cervical c-1)0.25
- Brain - Hippocampus0.2
- Brain - Substantia nigra0.16
- Prostate0.15
- Fallopian Tube0.13
- Colon - Sigmoid0.1
- Colon - Transverse0.1
- Bladder0.07
- Brain - Cerebellum0.07
- Ovary0.06
- Cervix - Endocervix0.06
- Kidney - Medulla0.05
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0007193
- GO:0007198
- GO:0007268
- GO:0014827
Cellular components
- GO:0005886
- GO:0001586
- GO:0004993
- GO:0005515
Related records
Trials (317)
- "Completeness of Response" Following Treatment With Treximetâ„¢ for Migraine
- A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches
- A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
- A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
- A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
- A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
- A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
- A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.
- A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects
- A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
- A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
- A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
- A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea And Vomiting in the Bariatric Surgery Population
- A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine
- A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
- A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine
- A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)
Drugs (28)
- Almotriptan Serotonin 1d (5-HT1d) receptor agonist
- Almotriptan malate Serotonin 1d (5-HT1d) receptor agonist
- Amisulpride Serotonin (5-HT) receptor antagonist
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Dihydroergotamine Serotonin 1d (5-HT1d) receptor agonist
- Dihydroergotamine mesylate Serotonin 1d (5-HT1d) receptor agonist
- Donitriptan Serotonin 1d (5-HT1d) receptor agonist
- Eletriptan Serotonin 1d (5-HT1d) receptor agonist
- Eletriptan hydrobromide Serotonin 1d (5-HT1d) receptor agonist
- Elzasonan Serotonin 1d (5-HT1d) receptor antagonist
- Elzasonan hydrochloride Serotonin 1d (5-HT1d) receptor antagonist
- Ergotamine Serotonin 1d (5-HT1d) receptor agonist
- Ergotamine tartrate Serotonin 1d (5-HT1d) receptor agonist
- Fenfluramine Serotonin 1d (5-HT1d) receptor agonist
- Fenfluramine hydrochloride Serotonin 1d (5-HT1d) receptor agonist
- Frovatriptan Serotonin 1d (5-HT1d) receptor agonist
- Frovatriptan succinate Serotonin 1d (5-HT1d) receptor agonist
- GSK163090 Serotonin 1d (5-HT1d) receptor antagonist
- Naratriptan Serotonin 1d (5-HT1d) receptor agonist